Abstract

Subchronic treatment with the psychotomimetic phencyclidine (PCP) has been proposed as a rodent model of the negative and cognitive/executive symptoms of schizophrenia. There has, however, been a paucity of studies on this model in mice, despite the growing use of the mouse as a subject in genetic and molecular studies of schizophrenia. In the present study, we evaluated the effects of subchronic PCP treatment (5 mg/kg twice daily × 7 days, followed by 7 days withdrawal) in C57BL/6J mice on (1) social behaviors using a sociability/social novelty-preference paradigm, and (2) pairwise visual discrimination and reversal learning using a touchscreen-based operant system. Results showed that mice subchronically treated with PCP made more visits to (but did not spend more time with) a social stimulus relative to an inanimate one, and made more visits and spent more time investigating a novel social stimulus over a familiar one. Subchronic PCP treatment did not significantly affect behavior in either the discrimination or reversal learning tasks. These data encourage further analysis of the potential utility of mouse subchronic PCP treatment for modeling the social withdrawal component of schizophrenia. They also indicate that the treatment regimen employed was insufficient to impair our measures of discrimination and reversal learning in the C57BL/6J strain. Further work will be needed to identify alternative methods (e.g., repeated cycles of subchronic PCP treatment, use of different mouse strains) that reliably produce discrimination and/or reversal impairment, as well as other cognitive/executive measures that are sensitive to chronic PCP treatment in mice.

Highlights

  • Schizophrenia is a heterogeneous disease characterized by positive, negative and cognitive/executive symptoms (DSM-IV, 1994)

  • Treatment with N-methyl-D-aspartate receptor (NMDAR) antagonists produce various behavioral abnormalities posited to be relevant to positive symptoms of schizophrenia (Arguello and Gogos, 2006; Powell and Miyakawa, 2006)

  • The number of transitions between the social and inanimate stimuli did not differ between saline- and PCPtreated mice (t = 0.80, df = 13, p = 0.439) (Figure 1D)

Read more

Summary

Introduction

Schizophrenia is a heterogeneous disease characterized by positive, negative and cognitive/executive symptoms (DSM-IV, 1994). Positive symptoms (so-called because they add to the normal behavioral repertoire) include hallucinations, psychomotor agitation and hypersensitivity to psychotomimetics. Treatment with NMDAR antagonists produce various behavioral abnormalities posited to be relevant to positive symptoms of schizophrenia (Arguello and Gogos, 2006; Powell and Miyakawa, 2006). Acute administration of the NMDAR antagonists PCP or MK-801 (dizocilpine) produces a profound locomotor hyperactivity that is reversible by antipsychotics. This drug response has been proposed as a measure relevant to positive symptoms in schizophrenia, and has been extensively studied as such (Arguello and Gogos, 2006; Powell and Miyakawa, 2006)

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call